88 related articles for article (PubMed ID: 24098014)
1. Approach to the patient: role of dosimetric RAI Rx in children with DTC.
Verburg FA; Reiners C; Hänscheid H
J Clin Endocrinol Metab; 2013 Oct; 98(10):3912-9. PubMed ID: 24098014
[TBL] [Abstract][Full Text] [Related]
2. I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer.
Verburg FA; Biko J; Diessl S; Demidchik Y; Drozd V; Rivkees SA; Reiners C; Hänscheid H
J Clin Endocrinol Metab; 2011 Aug; 96(8):E1268-71. PubMed ID: 21613356
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
[TBL] [Abstract][Full Text] [Related]
4. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry and thyroid cancer: the individual dosage of radioiodine.
Lassmann M; Reiners C; Luster M
Endocr Relat Cancer; 2010 Sep; 17(3):R161-72. PubMed ID: 20448022
[TBL] [Abstract][Full Text] [Related]
6. The use of dosimetry in the treatment of differentiated thyroid cancer.
Lassmann M; Hänscheid H; Verburg FA; Luster M
Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):107-15. PubMed ID: 21386785
[TBL] [Abstract][Full Text] [Related]
7. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
8. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
9. Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer.
Verburg FA; Hänscheid H; Luster M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):279-290. PubMed ID: 28911724
[TBL] [Abstract][Full Text] [Related]
10. [Lungs absorbed dose in radioiodine therapy of differentiated thyroid carcinoma with diffuse pulmonary metastases].
Liu B; Zeng Y; Wang J; Zhao Z; Mu D; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Aug; 27(4):851-4. PubMed ID: 20842858
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy.
Dong P; Wang L; Huang R; Li L
Medicine (Baltimore); 2020 Jul; 99(31):e21398. PubMed ID: 32756134
[TBL] [Abstract][Full Text] [Related]
12. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.
Blumhardt R; Wolin EA; Phillips WT; Salman UA; Walker RC; Stack BC; Metter D
Endocr Relat Cancer; 2014; 21(6):R473-84. PubMed ID: 25277792
[TBL] [Abstract][Full Text] [Related]
13. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
[TBL] [Abstract][Full Text] [Related]
14. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
[TBL] [Abstract][Full Text] [Related]
15. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
16. Lymph node metastases from differentiated thyroid carcinoma: does radioiodine still play a role?
Ronga G; Toteda M; D'Apollo R; De Cristofaro F; Filesi M; Acqualagna G; Argirò R; Ciancamerla M; Ugolini F; Montesano T
Clin Ter; 2012; 163(5):377-81. PubMed ID: 23099964
[TBL] [Abstract][Full Text] [Related]
17. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
18. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases.
De Klerk JM; Oyen WJ
Minerva Endocrinol; 2009 Mar; 34(1):57-69. PubMed ID: 19209128
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
Chow SM; Yau S; Lee SH; Leung WM; Law SC
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
